Boletín de AInvest
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
The cannabis sector stands at a pivotal crossroads in 2026, with federal tax reform poised to redefine its financial landscape. For contrarian investors, the removal of IRS Section 280E-a provision that has historically barred cannabis companies from deducting ordinary business expenses-represents not just a regulatory shift but a structural inflection point.

The U.S. cannabis industry's effective tax rate has long exceeded 70% due to Section 280E, which prohibits businesses from deducting costs like payroll, rent, and marketing.
, the reclassification of marijuana from Schedule I to Schedule III under the Controlled Substances Act could eliminate this burden, allowing operators to deduct standard expenses and significantly improve net margins. , which -a 63% improvement from the prior year-this reform could transform its cash flow profile. Similarly, , despite a $2.2 billion net loss driven by impairment charges, projects fiscal 2026 Adjusted EBITDA in the range of $62–72 million.Short interest data reveals a stark divide between market sentiment and fundamental potential. As of November 14, 2025, Tilray's short interest stood at 8.86% of its public float, with a days-to-cover ratio of 2.4
. For , short interest in the prior month but has since declined to 9.08%, reflecting a 15.7% reduction. These figures suggest growing skepticism among short sellers, yet they also hint at a potential short squeeze if the sector rallies ahead of tax reform.Institutional ownership trends further validate this narrative. Tilray's institutional ownership in Q4 2025 reached 9.35%, with major investors like Tidal Investments LLC and Vanguard Group Inc.
. Canopy, meanwhile, in Q4 2025, while UBS Group AG and TD Asset Management Inc. also added to their positions. These moves signal institutional confidence in the companies' ability to capitalize on regulatory tailwinds.Forward-looking financial models underscore the magnitude of the valuation reset. Canopy's Q2 FY2026 revenue
to $67 million CAD, driven by high-margin products like vapes and pre-rolls. With $298 million in cash and equivalents, the company has resolved concerns about its going-concern status. could reach $17 million by 2030, while Tilray's is expected to grow from $14.8 million in 2026 to $43 million by 2030 .The removal of Section 280E would amplify these metrics. For instance,
, and its craft beverage division contributed $10.2 million in Adjusted EBITDA. If tax reform allows full expense deductions, its EBITDA margins could expand further, aligning with industry multiples that currently undervalue cannabis operators.Canopy's asset-light model and strategic focus on the U.S. market
if federal policy changes. Its leaner structure, combined with $21 million in annualized cost reductions, suggests a path to profitability . Tilray's diversified approach-spanning cannabis, wellness, and alcohol-provides financial stability, though its cannabis segment revenue declined 9% in the most recent fiscal year. has also improved its institutional appeal by raising its share price above $5.00.The 2026 cannabis tax reform is not merely a regulatory adjustment but a catalyst for sector-wide valuation resets. With short interest acting as a contrarian indicator and institutional ownership signaling emerging confidence, oversold leaders like
and Tilray Brands present compelling entry points. As the industry transitions from a cash-burn model to one of sustainable free cash flow, early investors stand to benefit from a re-rating that could outpace broader market expectations.Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
Comentarios
Aún no hay comentarios